glp-1 news 2025 november 25 Consumers' Expectations about Drugs Economic Impact on Food System Players 2025 ADA Highlights: A New

A critical analysis of recent literature highlights the importance of integrative and cautious approaches that account for the developmental plasticity of the pediatric organism and the possible pleiotropic effects of early pharmacological intervention.

Senior Litigation Counsel Jason Goldstein of Parker Waichman LLP appointed Co-Chair of the Plaintiffs Executive Committee in MDL 3163.

Objective To assess whether use of glucagon-like peptide-1 (GLP-1) receptor agonists before upper gastrointestinal endoscopy is associated with increased risk of pulmonary aspiration or discontinuation of the procedure compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitors

Our preclinical findings highlight its potential therapeutic use for patients

Explore how Boost Synergy GLP-1 may support appetite control, gut health, blood sugar balance, and mood

Conclusions Twenty-four weeks of acarbose monotherapy in newly diagnosed patients with T2D is associated with significantly increased levels of both fasting and postprandial GLP-1 as well as significantly increased NO levels and NOS activity for those patients in whom postprandial GLP-1 levels were increased